Home › Funds › PSP Research LLC › PTGX
PSP Research LLC position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
PSP Research LLC reported holding 1,500 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$211K, representing 0.14% of its reported portfolio and ranking #36 among its reported holdings. PSP Research LLC has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR
How PSP Research LLC's PTGX position evolved
PSP Research LLC first disclosed a stake in PTGX in Q4 2025 at 6,121 shares (US$535K). Across 4 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,500 shares valued at US$211K — a reduction of -1,500 shares quarter over quarter.. Notable position changes include a 51% trim in Q1 2026 (shares rose 16% over the following quarter), a 50% trim in Q3 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 6.12K | $534.61K | New |
| Q1 2026 | 3.00K | $316.20K | Reduce |
| Q2 2026 | 3.00K | $367.74K | Hold |
| Q3 2026 | 1.50K | $211.34K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $300.22M · Q2 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K sh · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- Eagle Health Investments LP 248.32K sh · $30.44M · Q2 2026
More on PSP Research LLC
FAQ
How long has PSP Research LLC held PTGX?
PSP Research LLC has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is PSP Research LLC's current position in PTGX?
As of Q3 2026, PSP Research LLC holds 1.50K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $211.34K, representing 0.14% of its reported portfolio and ranking #36.
Has PSP Research LLC been buying or selling PTGX?
In the latest 13F filing (Q3 2026), PSP Research LLC reduced its position in PTGX.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.